Matches in Wikidata for { <http://www.wikidata.org/entity/Q65473849> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q65473849 description "clinical trial" @default.
- Q65473849 description "ensayu clínicu" @default.
- Q65473849 description "klinisch onderzoek" @default.
- Q65473849 description "клінічне випробування" @default.
- Q65473849 name "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 name "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 type Item @default.
- Q65473849 label "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 label "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 prefLabel "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 prefLabel "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 P1050 Q65473849-FF6EBB86-0C36-49D5-90A6-D53D715FA590 @default.
- Q65473849 P1132 Q65473849-4F155D72-07C2-4D0E-ADBA-113098167F4A @default.
- Q65473849 P1476 Q65473849-3CCECFF0-0F9F-46A3-AC68-E05CE411F678 @default.
- Q65473849 P17 Q65473849-16569E4C-6671-4493-9B6D-4DAC4CE88B8B @default.
- Q65473849 P17 Q65473849-3DF1102D-6D73-412F-AFE5-581FEE2FE8E7 @default.
- Q65473849 P17 Q65473849-65975406-E5D7-4BEE-A245-4E1034BF0D2D @default.
- Q65473849 P17 Q65473849-90D97429-C408-4F5B-9568-17ADE4C0B390 @default.
- Q65473849 P17 Q65473849-A42C8037-E100-46E6-A4C4-32E887B6EB25 @default.
- Q65473849 P17 Q65473849-ADBFB789-E691-48B2-9BBF-2BA0E9DCA343 @default.
- Q65473849 P17 Q65473849-B82F3590-98A5-4F91-A7CE-E79CC4606965 @default.
- Q65473849 P17 Q65473849-D7C8FD28-5440-4BE5-8824-7A290484CD7C @default.
- Q65473849 P17 Q65473849-F714E744-7A9D-42CC-A1ED-3756173AF455 @default.
- Q65473849 P2899 Q65473849-650931AE-A5F4-429C-98CF-9B0E6220DAFB @default.
- Q65473849 P3098 Q65473849-663FF58B-6DE6-4038-ABCF-0DB14588519D @default.
- Q65473849 P31 Q65473849-4F9E284B-5E3E-489C-8F8A-9CC2E44C9277 @default.
- Q65473849 P4135 Q65473849-161455E4-0272-4123-A4B9-EBFE0807A90F @default.
- Q65473849 P580 Q65473849-7ABD54FA-FECA-40DE-A232-7B6BE6E56AB7 @default.
- Q65473849 P582 Q65473849-4C25ABE0-3843-49D1-9801-B7C8AB828C1E @default.
- Q65473849 P6099 Q65473849-72DAFE3A-C85A-4DF1-8C30-92E4A299CA64 @default.
- Q65473849 P6153 Q65473849-23C2AB44-E05D-4735-B4C3-27087409524C @default.
- Q65473849 P6153 Q65473849-38CF067E-044E-4DD5-9A0A-676A45840D06 @default.
- Q65473849 P6153 Q65473849-686C24A6-5A32-418B-B4EB-B4902BE88D50 @default.
- Q65473849 P6153 Q65473849-6DC606BC-6A01-4702-8DE1-B55875AB4D66 @default.
- Q65473849 P6153 Q65473849-DF96C8A1-F899-4480-9BF5-9A0BE2BD0568 @default.
- Q65473849 P6153 Q65473849-E85DC72B-B143-4DB4-8DBC-B2390B110955 @default.
- Q65473849 P6153 Q65473849-F5A79069-A1EC-40E0-B8AA-31CCD6AECDB2 @default.
- Q65473849 P8363 Q65473849-67EB79C7-F6E6-4543-98DF-4DF2CAEC4BB5 @default.
- Q65473849 P1050 Q12206 @default.
- Q65473849 P1132 "+677" @default.
- Q65473849 P1476 "A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere /Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up" @default.
- Q65473849 P17 Q145 @default.
- Q65473849 P17 Q155 @default.
- Q65473849 P17 Q16 @default.
- Q65473849 P17 Q29 @default.
- Q65473849 P17 Q298 @default.
- Q65473849 P17 Q30 @default.
- Q65473849 P17 Q36 @default.
- Q65473849 P17 Q414 @default.
- Q65473849 P17 Q96 @default.
- Q65473849 P2899 "+18" @default.
- Q65473849 P3098 "NCT00309244" @default.
- Q65473849 P31 Q30612 @default.
- Q65473849 P4135 "+80" @default.
- Q65473849 P580 "2006-02-01T00:00:00Z" @default.
- Q65473849 P582 "2008-08-01T00:00:00Z" @default.
- Q65473849 P6099 Q42824827 @default.
- Q65473849 P6153 Q1134710 @default.
- Q65473849 P6153 Q2471216 @default.
- Q65473849 P6153 Q30269696 @default.
- Q65473849 P6153 Q30289162 @default.
- Q65473849 P6153 Q349055 @default.
- Q65473849 P6153 Q4117596 @default.
- Q65473849 P6153 Q5902966 @default.
- Q65473849 P8363 Q78089383 @default.